Top 10 Companies in the Iopamidol API Market (2026): Market Leaders Driving Global Diagnostic Innovation

MARKET INSIGHTS

Global Iopamidol API market size was valued at USD 255 million in 2024. The market is projected to grow from USD 268 million in 2025 to USD 360.97 million by 2032, exhibiting a CAGR of 4.40% during the forecast period.

Iopamidol is a non-ionic, water‑soluble contrast medium used extensively in X‑ray and computed tomography (CT) imaging procedures. As an active pharmaceutical ingredient (API), it enhances radiographic visualization of blood vessels, organs, and body cavities. Its superior safety profile and low osmolarity make it particularly valuable for angiography, urography, and myelography applications.

The market growth is driven by increasing diagnostic imaging demand, particularly in emerging economies, coupled with rising prevalence of chronic diseases requiring advanced imaging. North America currently dominates the market, with its Iopamidol API segment valued at USD 72 million in 2024. However, Asia‑Pacific is projected to witness the fastest growth due to expanding healthcare infrastructure and increasing medical tourism. Key players like Bracco Imaging and Stellite continue to innovate production processes to meet growing global demand while maintaining stringent quality standards.

Iopamidol API Market – View in Detailed Research Report

Market Size Overview

In 2024, the global Iopamidol API market reached USD 255 million, with an anticipated rise to USD 360.97 million by 2032. This reflects a steady CAGR of 4.40%, underscoring robust growth in diagnostic imaging worldwide.

Product Definition

Iopamidol is a non‑ionic, low‑osmolar iodinated contrast agent that provides high‑contrast imaging in CT and X‑ray procedures. Its rapid distribution, minimal adverse reactions, and excellent safety profile make it the preferred choice for clinicians seeking precise diagnostic information.

Top 10 Companies in the Iopamidol API Market (2026)

1. Bracco Imaging S.p.A. (Italy)

   Headquarters: Milan, Italy
   Key Offering: Iopamidol API for contrast‑enhanced CT, X‑ray, and interventional radiology.

   Bracco has invested heavily in GMP‑certified facilities across Europe and North America, ensuring consistent supply and quality. The company also focuses on low‑osmolar formulations to reduce nephrotoxicity.

   Strategic Initiatives:

   • Expansion of API production capacity in the U.S. and China.
   • Investment in AI‑driven imaging analytics to optimize contrast dosing.
   • Partnerships with major hospital networks to streamline distribution.

2. Guerbet Group (France)

   Headquarters: Paris, France
   Key Offering: High‑purity Iopamidol for diagnostic imaging and interventional procedures.

   Guerbet’s global presence and strong hospital collaborations enable rapid market penetration, especially in emerging Asian markets.

   Strategic Initiatives:

   • Launch of a new low‑osmolar Iopamidol line.
   • Investment in green chemistry to reduce waste.
   • Collaborations with local manufacturers in India and Brazil.

3. Lantheus Medical Imaging (United States)

   Headquarters: Westford, Massachusetts, USA
   Key Offering: Iopamidol API for CT and X‑ray contrast imaging.

   Lantheus focuses on high‑grade API production, ensuring compliance with FDA and EMA standards.

   Strategic Initiatives:

   • Expansion of GMP facilities in Texas.
   • Research into iso‑osmolar variants.
   • Strategic alliances with diagnostic centers in the Middle East.

4. Stellite (China)

   Headquarters: Shanghai, China
   Key Offering: Cost‑effective generic Iopamidol API.

   Stellite’s rapid scale‑up of production has positioned it as a leading generic supplier in Asia.

   Strategic Initiatives:

   • Investment in advanced purification technologies.
   • Partnerships with regional hospitals in Southeast Asia.
   • Focus on regulatory compliance for export markets.

5. Jiangsu Hengrui Medicine Co., Ltd. (China)

   Headquarters: Nanjing, China
   Key Offering: High‑purity Iopamidol API for diagnostic imaging.

   Hengrui leverages its R&D capabilities to develop low‑osmolar formulations.

   Strategic Initiatives:

   • Expansion of API manufacturing in Chongqing.
   • Collaboration with European distributors.
   • Investment in sustainability practices.

6. Sun Pharmaceutical Industries Ltd. (India)

   Headquarters: Mumbai, India
   Key Offering: Generic Iopamidol API.

   Sun Pharma’s global footprint and regulatory approvals in 40+ countries accelerate market access.

   Strategic Initiatives:

   • Acquisition of a GMP facility in Pune.
   • Partnership with Indian diagnostic centers.
   • Focus on cost‑effective production.

7. General Electric Healthcare (United States)

   Headquarters: Boston, Massachusetts, USA
   Key Offering: Iopamidol API for advanced imaging solutions.

   GE Healthcare integrates its imaging platforms with high‑quality API to offer end‑to‑end solutions.

   Strategic Initiatives:

   • Investment in AI‑based imaging analytics.
   • Expansion of API production in Texas.
   • Collaboration with European hospital networks.

8. Sanochemia Pharmazeutika AG (Austria)

   Headquarters: Vienna, Austria
   Key Offering: Pharmaceutical‑grade Iopamidol API.

   Sanochemia focuses on high‑purity production for European and U.S. markets.

   Strategic Initiatives:

   • Investment in green chemistry.
   • Partnerships with research institutes.
   • Expansion of GMP facilities.

9. Hikma Pharmaceuticals PLC (United Kingdom)

   Headquarters: London, United Kingdom
   Key Offering: Generic Iopamidol API.

   Hikma’s extensive global distribution network supports rapid market entry.

   Strategic Initiatives:

   • Expansion of production in the UK and the Middle East.
   • Investment in low‑cost manufacturing technologies.
   • Partnerships with diagnostic centers in Africa.

10. Guerbet Group (France)

    Headquarters: Paris, France
    Key Offering: High‑purity Iopamidol API for diagnostic imaging.

    Guerbet’s strong presence in Europe and North America underpins its market leadership.

    Strategic Initiatives:

    • Expansion of API production in Germany.
    • Investment in advanced purification processes.
    • Collaboration with U.S. diagnostic centers.

Download FREE Sample Report

Get Full Report

Market Outlook

The Iopamidol API market is poised for steady expansion, driven by the growing adoption of advanced imaging technologies and the increasing prevalence of chronic diseases. North America will maintain its leadership position, while Asia‑Pacific is expected to deliver the highest CAGR due to rapid healthcare infrastructure development and rising medical tourism. Continued innovation in low‑osmolar and iso‑osmolar formulations will further bolster demand.

Future Trends

• Integration of AI‑driven dosing algorithms to optimize contrast usage.
• Expansion of generic Iopamidol production to meet cost‑sensitivity in emerging markets.
• Adoption of green chemistry to reduce environmental impact.
• Strategic collaborations between API manufacturers and imaging platform vendors.
• Growth of tele‑medicine and remote imaging services, amplifying API demand.